PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.40 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

PharmaCyte Biotech (PMCB) Gains from Sales and Divestitures (2009 - 2010)

Updated

PharmaCyte Biotech (PMCB) posted Gains from Sales and Divestitures of -$1.57 million for FY2024 (year ended Apr 30, 2024).

Analysis

PharmaCyte Biotech (PMCB) Gains from Sales and Divestitures (2009 - 2010) Analysis & Trends

  • The FY2024 figure stands as the highest annual Gains from Sales and Divestitures since FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 PharmaCyte Biotech 4.29 Mn -68.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2010 127.00
Jul 31, 2009 529.00
API Access

PharmaCyte Biotech Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PMCB&period=max&api_key=YOUR_API_KEY